XML 104 R88.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity - RSUs, Revest Shares, Narrative (Details)
12 Months Ended
Jan. 31, 2022
USD ($)
Oct. 01, 2020
cofounder
shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
cofounder
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense     $ 145,796,000 $ 140,488,000 $ 64,433,000
Signal Sciences Corp          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of cofounders with shares subject to revesting | cofounder   3     3
Shares held back for restricted stock awards, revesting period   2 years     2 years
Signal Sciences Corp | Common Class A          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares restricted for stock awards (in shares) | shares   896,499     896,499
RSUs          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period     4 years    
Granted (in dollars per share) | $ / shares     $ 14.63 $ 54.92 $ 31.22
Vested in period, grant date fair value     $ 97,900,000 $ 67,700,000 $ 31,600,000
Stock-based compensation expense     98,500,000 78,300,000 45,300,000
Expense related to modification     1,900,000 2,800,000 $ 4,800,000
Unrecognized stock-based compensation cost     $ 224,700,000    
Weighted-average period of recognition     2 years 8 months 12 days    
RSUs | First Year          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period     4 years    
Award vesting percentage per year     25.00%    
RSUs | Remaining Period          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period     36 months    
RSAs          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense     $ 27,600,000 $ 43,800,000  
Unrecognized stock-based compensation cost     0    
Nonvested shares sold that remain unvested (in shares) | shares       224,124  
Proceeds from nonvested shares sold $ 10,700,000        
Incremental cost due to plan modification     $ 5,600,000 $ 0